Ack1-mediated androgen receptor phosphorylation modulates radiation resistance in castration-resistant prostate cancer

Journal of Biological Chemistry

Volumn 287, Issue 26, 2012, Pages 22112-22122

  Mahajan, Kiran ^a   Coppola, Domenico ^a   Rawal, Bhupendra ^a   Chen, Y Ann ^a   Lawrence, Harshani R ^a   Engelman, Robert W ^a   Lawrence, Nicholas J ^a   Mahajan, Nupam P ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; ANDROGEN RECEPTORS; ATAXIA-TELANGIECTASIA MUTATED; INCURABLE DISEASE; INITIAL STAGES; MOLECULAR MECHANISM; PROSTATE CANCERS; RADIATION RESISTANCE; RADIORESISTANCE; RECURRENT CANCER; TYROSINE KINASE;

AMINO ACIDS; DISEASES; PHOSPHORYLATION; RADIOTHERAPY;

INTERNET PROTOCOLS;

AIM 100; ANDROGEN RECEPTOR; ATM PROTEIN; PROTEIN ACK1; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENHANCER REGION; ENZYME ACTIVATION; ENZYME REGULATION; GAMMA IRRADIATION; GENETIC ENGINEERING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; UPREGULATION;

ANIMALS; CELL CYCLE PROTEINS; DNA DAMAGE; DNA-BINDING PROTEINS; ENHANCER ELEMENTS, GENETIC; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; MALE; MICE; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; RADIATION TOLERANCE; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84862693127     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.357384     Document Type: Article

References (41)

1. Mahajan, N. P., Whang, Y. E., Mohler, J. L., and Earp, H. S. (2005) Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: Role of Ack1 in polyubiquitination of tumor suppressor Wwox. Cancer Res. 65, 10514-10523
2. Mahajan, N. P., Liu, Y., Majumder, S., Warren, M. R., Parker, C. E., Mohler, J. L., Earp, H. S., and Whang, Y. E. (2007) Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc. Natl. Acad. Sci. U.S.A. 104, 8438-8443
3. Mahajan, K., Coppola, D., Challa, S., Fang, B., Chen, Y. A., Zhu, W., Lopez, A. S., Koomen, J., Engelman, R. W., Rivera, C., Muraoka-Cook, R. S., Cheng, J. Q., Schönbrunn, E., Sebti, S. M., Earp, H. S., and Mahajan, N. P. (2010) Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation. PLoS One 5, e9646
4. Mahajan, K., and Mahajan, N. P. (2010) Shepherding AKT and androgen receptor by Ack1 tyrosine kinase. J. Cell Physiol. 224, 327-333
5. Mahajan, K., and Mahajan, N. P. (February 3, 2012) J. Cell. Physiol., 10.1002/jcp.24065. [Epub ahead of print]
6. Mahajan, K., Coppola, D., Chen, Y. A., Zhu, W., Lawrence, H. R., Lawrence, N. J., and Mahajan, N. P. (2012) Ack1 tyrosine kinase activation correlates with pancreatic cancer progression. Am. J. Pathol. 180, 1386-1393
7. van der Horst, E. H., Degenhardt, Y. Y., Strelow, A., Slavin, A., Chinn, L., Orf, J., Rong, M., Li, S., See, L. H., Nguyen, K. Q., Hoey, T., Wesche, H., and Powers, S. (2005) Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1. Proc. Natl. Acad. Sci. U.S.A. 102, 15901-15906
8. Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., Antipin, Y., Mitsiades, N., Landers, T., Dolgalev, I., Major, J. E., Wilson, M., Socci, N. D., Lash, A. E., Heguy, A., Eastham, J. A., Scher, H. I., Reuter, V. E., Scardino, P. T., Sander, C., Sawyers, C. L., and Gerald, W. L. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22
9. Prieto-Echagüe, V., Gucwa, A., Craddock, B. P., Brown, D. A., and Miller, W. T. (2010) Cancer-associated mutations activate the nonreceptor tyrosine kinase Ack1. J. Biol. Chem. 285, 10605-10615
10. Mahajan, K., Challa, S., Coppola, D., Lawrence, H., Luo, Y., Gevariya, H., Zhu, W., Chen, Y. A., Lawrence, N. J., and Mahajan, N. P. (2010) Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity. Prostate 70, 1274-1285
11. Yokoyama, N., and Miller, W. T. (2003) Biochemical properties of the Cdc42-associated tyrosine kinase ACK1. Substrate specificity, authphosphorylation, and interaction with Hck. J. Biol. Chem. 278, 47713-47723
12. Litvinov, I. V., De Marzo, A. M., and Isaacs, J. T. (2003) Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J. Clin. Endocrinol. Metab. 88, 2972-2982
13. Chen, Y., Sawyers, C. L., and Scher, H. I. (2008) Targeting the androgen receptor pathway in prostate cancer. Cur. Opin. Pharmacol. 8, 440-448
14. Attar, R. M., Takimoto, C. H., and Gottardis, M. M. (2009) Castration-resistant prostate cancer: Locking up the molecular escape routes. Clin. Cancer Res. 15, 3251-3255
15. Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., and Sawyers, C. L. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33-39
16. Waltering, K. K., Helenius, M. A., Sahu, B., Manni, V., Linja, M. J., Jänne, O. A., and Visakorpi, T. (2009) Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res. 69, 8141-8149
17. Jackson, S. P., and Bartek, J. (2009) The DNA-damage response in human biology and disease. Nature 461, 1071-1078
18. Kastan, M. B. (2008) DNA damage responses: Mechanisms and roles in human disease: 2007 G.H.A. Clowes Memorial Award Lecture. Mol. Cancer Res. 6, 517-524
19. Bakkenist, C. J., and Kastan, M. B. (2003) DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421, 499-506
20. Shiloh, Y. (2003) ATM and related protein kinases: Safeguarding genome integrity. Nat. Rev. Cancer 3, 155-168
21. Matsuoka, S., Ballif, B. A., Smogorzewska, A., McDonald, E. R., 3rd, Hurov, K. E., Luo, J., Bakalarski, C. E., Zhao, Z., Solimini, N., Lerenthal, Y., Shiloh, Y., Gygi, S. P., and Elledge, S. J. (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316, 1160-1166
22. Fang, Z., Kozlov, S., McKay, M. J., Woods, R., Birrell, G., Sprung, C. N., Murrell, D. F., Wangoo, K., Teng, L., Kearsley, J. H., Lavin, M. F., Graham, P. H., and Clarke, R. A. (2010) Low levels of ATM in breast cancer patients with clinical radiosensitivity. Genome Integr. 1, 9
23. Cesaretti, J. A., Stock, R. G., Lehrer, S., Atencio, D. A., Bernstein, J. L., Stone, N. N., Wallenstein, S., Green, S., Loeb, K., Kollmeier, M., Smith, M., and Rosenstein, B. S. (2005) ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 61, 196-202
24. Pugh, T. J., Keyes, M., Barclay, L., Delaney, A., Krzywinski, M., Thomas, D., Novik, K., Yang, C., Agranovich, A., McKenzie, M., Morris, W. J., Olive, P. L., Marra, M. A., and Moore, R. A. (2009) Sequence variant discovery in DNA repair genes from radiosensitive and radiotolerant prostate brachytherapy patients. Clin. Cancer Res. 15, 5008-5016
25. Salic, A., and Mitchison, T. J. (2008) A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc. Natl. Acad. Sci. U.S.A. 105, 2415-2420
26. Mahajan, K. N., and Mitchell, B. S. (2003) Role of human Pso4 in mammalian DNA repair and association with terminal deoxynucleotidyl transferase. Proc. Natl. Acad. Sci. U.S.A. 100, 10746-10751
27. Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., Wu, T., Regan, M. M., Meyer, C. A., Carroll, J. S., Manrai, A. K., Jänne, O. A., Balk, S. P., Mehra, R., Han, B., Chinnaiyan, A. M., Rubin, M. A., True, L., Fiorentino, M., Fiore, C., Loda, M., Kantoff, P. W., Liu, X. S., and Brown, M. (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138, 245-256
28. DiMauro, E. F., Newcomb, J., Nunes, J. J., Bemis, J. E., Boucher, C., Buchanan, J. L., Buckner, W. H., Cheng, A., Faust, T., Hsieh, F., Huang, X., Lee, J. H., Marshall, T. L., Martin, M. W., McGowan, D. C., Schneider, S., Turci, S. M., White, R. D., and Zhu, X. (2007) Discovery of 4-amino-5,6-biaryl- furo[2,3-D[rsqb]pyrimidines as inhibitors of Lck: Development of an expedient and divergent synthetic route and preliminary SAR. Bioorg. Med. Chem. Lett. 17, 2305-2309
29. Savitsky, K., Bar-Shira, A., Gilad, S., Rotman, G., Ziv, Y., Vanagaite, L., Tagle, D. A., Smith, S., Uziel, T., Sfez, S., Ashkenazi, M., Pecker, I., Frydman, M., Harnik, R., Patanjali, S. R., Simmons, A., Clines, G. A., Sartiel, A., Gatti, R. A., Chessa, L., Sanal, O., Lavin, M. F., Jaspers, N. G., Taylor, A. M., Arlett, C. F., Miki, T., Weissman, S. M., Lovett, M., Collins, F. S., and Shiloh, Y. (1995) A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268, 1749-1753
30. Berkovich, E., and Ginsberg, D. (2003) ATM is a target for positive regulation by E2F-1. Oncogene 22, 161-167
31. Kastan, M. B., Lim, D. S., Kim, S. T., and Yang, D. (2001) ATM- a key determinant of multiple cellular responses to irradiation. Acta Oncologica 40, 686-688
32. Lee, J. H., and Paull, T. T. (2007) Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene 26, 7741-7748
33. Lee, J. H., and Paull, T. T. (2005) ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science 308, 551-554
34. Hickson, I., Zhao, Y., Richardson, C. J., Green, S. J., Martin, N. M., Orr, A. I., Reaper, P. M., Jackson, S. P., Curtin, N. J., and Smith, G. C. (2004) Identification and characterization of a novel and specific inhibitor of the ataxia telangiectasia-mutated kinase ATM. Cancer Res. 64, 9152-9159
35. Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., and Rich, J. N. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760
36. Cheng, L., Wu, Q., Huang, Z., Guryanova, O. A., Huang, Q., Shou, W., Rich, J. N., and Bao, S. (2011) L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1. EMBO J. 30, 800-813
37. Bartek, J., and Lukas, J. (2007) DNA damage checkpoints: From initiation to recovery or adaptation. Curr. Opin. Cell Biol. 19, 238-245
38. 2 phase cells. Cell Cycle 6, 1682-1686
39. Rainey, M. D., Charlton, M. E., Stanton, R. V., and Kastan, M. B. (2008) Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res. 68, 7466-7474
40. 2 checkpoint abrogators as anticancer drugs. Mol. Cancer Ther. 3, 513-519
41. Di Lorenzo, G., Buonerba, C., Autorino, R., De Placido, S., and Sternberg, C. N. (2010) Castration-resistant prostate cancer: Current and emerging treatment strategies. Drugs 70, 983-1000